Announcements Trials
Browse Landscape

Phase

Phase NA 30Phase 2 16Phase 3 7Phase 4 5Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 276Pain, Postoperative 14Neoplasm Metastasis 12Neoplasms 9Prostatic Neoplasms 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Pain 6Osteoporosis 6Seroma 5Colorectal Neoplasms 5Cardiotoxicity 5Breast Diseases 4Breast Cancer Female 4Neutropenia 3Melanoma 3Mastodynia 3Lymphedema 3Lung Neoplasms 3Head and Neck Neoplasms 3Brain Neoplasms 3Bone Diseases, Metabolic 3Vomiting 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sleep Initiation and Maintenance Disorders 2Skin Diseases 2Obesity 2Neurotoxicity Syndromes 2Multiple Myeloma 2

Interventions

sacubitril and valsartan sodium hydrate drug combination 1Trastuzumab 1Tablets 1Silymarin 1Rosuvastatin Calcium 1Carnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × Cardiotoxicity × Breast × Clear all
NCT04928261 2026-01-22

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
52 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT02696707 2025-12-18

OTT 15-05

Ottawa Hospital Research Institute

Phase 4 Completed
200 enrolled 8 charts
Breast

Breast Neoplasms, Cardiotoxicity

NCT07254221 2025-12-10

ROSUBREAST

Shiraz University of Medical Sciences

Phase 4 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

NCT04434404 2020-06-16

Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy

Horus University

Phase 4 Completed
83 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡